Lancet oncol: Lofatini and Pym sabuta-resistant combination treatment for advanced stomach cancer

Pymsone is an anti-PD-1 antibody, used in the advanced stage of pD-L1 positive total score of 1stomach cancerpatients tumor remission rate of about 15%Lombardinis is a multikine inhibitor of VEGF receptors and other receptor tyrosine kinases, and in a living model, Lofatinib significantly reduces tumor-related macrophages, increases CD8 T-cell immersion, and thus enhances tumor activity of PD-1 inhibitorsThe purpose of this study was to evaluate the efficacy of the Lenfarini united pimzumab for advanced stomach cancerThis study is an open single-arm Phase 2 clinical trial that recruits metastatic or recurrent gastric adenocarcinoma sororoid adenocarcinoma scored 2 or 1 in the age of 20 and requires an ECOG performance score of 0 or 1Give Remberinib 20mg oral 1/day-phimsone 200mg static drop let alone drop 1/3 week, until the condition progresses or becomes intolerable toxicity or withdrawal testThe main endpoint is the objective mitigation rate (according to the RECIST assessment)15 October 2018 - 25 March 2019, a total of 29 patients were recruited for first- or second-line treatmentAs of March 20, 2020, the median follow-up was 12.6 months (IQR 10.5-14.3)Twenty (69%) patients received objective remissionThe most common level 3 treatment-related adverse reactions were hypertension (11 cases, 38%), proteinuria (5 cases, 17%) and decreased platelet count (2 cases, 7%)No level 4 treatment-related adverse reactions, severe treatment-related adverse reactions or treatment-related deathsThe use of The Lunvastini United Pym satag for advanced gastric cancer patients shows exciting anti-tumor activity and acceptable safetyBased on these results, further validation tests can be conducted